Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes

Hypertension

Volumn 52, Issue 4, 2008, Pages 721-728

  Rossier, Michel F ^a,c   Lenglet, Sébastien ^a   Vetterli, Laurène ^a   Python, Magaly ^a   Maturana, Andrés ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c University Hospital   (Switzerland)

Author keywords

Angiotensin II; Arrhythmias; Cardiomyocyte; Contraction; Corticosteroid; Glucocorticoid receptor; Mineralocorticoid receptor; Redox potential

Indexed keywords

ALDOSTERONE; CORTICOSTEROID; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CHRONOTROPISM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEART ARRHYTHMIA; HEART CONTRACTION; HEART MUSCLE CELL; HEART VENTRICLE; NEWBORN; NONHUMAN; OXIDATION; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; RAT; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; HEART VENTRICLES; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; OXIDATION-REDUCTION; RATS; RATS, WISTAR; RECEPTORS, GLUCOCORTICOID;

EID: 54749104730     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.114223     Document Type: Article

References (31)

1. Ramires FJ, Mansur A, Coelho O, Maranhao M, Gruppi CJ, Mady C, Ramires JA. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 2000;85:1207-1211.
2. Cittadini A, Monti MG, Isgaard J, Casaburi C, Stromer H, Di Gianni A, Serpico R, Saldamarco L, Vanasia M, Sacca L. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res. 2003;58:555-564.
3. Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A, Paliensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
4. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
5. Rocha R, Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs. 2002;62:723-731.
6. Chai W, Danser AH. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch Pharmacol. 2006;374:153-162.
7. Yoshimoto T, Hirata Y. Aldosterone as a cardiovascular risk hormone. Endocrinol J. 2007;54:359-370.
8. Pearce P, Funder JW. High affinity aldosterone binding sites (type I receptors) in rat heart. Clin Exp Pharmacol Physiol. 1987;14:859-866.
9. Funder JW. Is aldosterone bad for the heart? Trends Endocrinol Metab. 2004;15:139-142.
10. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Cat AN, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-3033.
11. Lalevee N, Rebsamen MC, Barrere-Lemaire S, Perrier E, Nargeot J, Benitah JP, Rossier MF. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;67:216-224.
12. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci U S A. 1983;80:6056-6060.
13. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003;93:69-76.
14. Springhorn JP, Claycomb WC. Preproenkephalin mRNA expression in developing rat heart and in cultured ventricular cardiac muscle cells. Biochem J. 1989;258:73-78.
15. Mihailidou AS, Funder JW. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids. 2005;70:347-351.
16. Piwien-Pilipuk G, Galigniana MD. Oxidative stress induced by L-buthionine-(S,R)-sulfoximine, a selective inhibitor of glutathione metabolism, abrogates mouse kidney mineralocorticoid receptor function. Biochim Biophys Acta. 2000;1495:263-280.
17. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure because of systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15:79-87.
18. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039-1045.
19. Abdo A, Bebb RA, Wilkins GE. Ventricular fibrillation: an extreme presentation of primary hyperaldosteronism. Can J Cardiol. 1999;15:347-348.
20. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
21. Geist M, Dorian P, Davies T, Greene M, Newman D. Hyperaldosteronism and sudden cardiac death. Am J Cardiol. 1996;78:605-606.
22. Ram R, Van Wagoner DR. Aldosterone antagonism as an antiarrhythmic approach for atrial arrhythmias in heart failure. J Cardiovasc Electrophysiol. 2006;17:542-543.
23. Barbuti A, Baruscotti M, DiFrancesco D. The pacemaker current: from basics to the clinics. J Cardiovasc Electrophysiol. 2007;18:342-347.
24. Vassort G, Talavera K, Alvarez JL. Role of T-type Ca2+ channels in the heart. Cell Calcium. 2006;40:205-220.
25. Hoppe UC, Jansen E, Sudkamp M, Beuckelmann DJ. Hyperpolarization- activated inward current in ventricular myocytes from normal and failing human hearts. Circulation. 1998;97:55-65.
26. Huang B, Qin D, Deng L, Boutjdir M, Sherif N. Reexpression of T-type Ca2+ channel gene and current in post-infarction remodeled rat left ventricle. Cardiovasc Res. 2000;46:442-449.
27. Beuckelmann DJ, Nabauer M, Erdmann E. Characteristics of calcium-current in isolated human ventricular myocytes from patients with terminal heart failure. J Mol Cell Cardiol. 1991;23:929-937.
28. Losel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol. 2003;4:46-56.
29. Young MJ, Funder JW. The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol. 1996;271:E883-E888.
30. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Stork S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754-1761.
31. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:656-664.